.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Baxter
Deloitte
Queensland Health
Cerilliant
Chinese Patent Office
Federal Trade Commission
Harvard Business School
Fish and Richardson
Citi
Dow

Generated: June 29, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,589,960

« Back to Dashboard

Which drugs does patent 6,589,960 protect, and when does it expire?


Patent 6,589,960 protects DILAUDID, DILAUDID-HP, and PALLADONE, and is included in four NDAs. There have been zero Paragraph IV challenges on Dilaudid and Dilaudid-HP

This patent has seventeen patent family members in nine countries.

Summary for Patent: 6,589,960

Title: Hydromorphone and hydrocodone compositions and methods for their synthesis
Abstract:A method for the preparation of a ketone from a narcotic alkaloid having an allyl alcohol moiety is disclosed. The method includes mixing the narcotic alkaloid with an acid in the presence of a catalyst wherein the method is carried out in the substantial absence of hydrogen gas. The method is useful for preparing hydromorphone and hydrocodone compositions having novel impurity profiles. Compositions comprising hydromorphone and hydrocodone are also disclosed.
Inventor(s): Harclerode; William H. (Asbury, NJ), Gault; Robert (Gross Pointe Woods, MI), Sandison; Mark D. (Dearborn, MI)
Assignee: Abbott Laboratories (Abbott Park, IL)
Application Number:10/256,996
Patent Claim Types:
see list of patent claims
Composition; Process; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Fresenius Kabi Usa
DILAUDID
hydromorphone hydrochloride
INJECTABLE;INJECTION019034-003Apr 30, 2009APRXYesYes6,589,960► SubscribeYY
Fresenius Kabi Usa
DILAUDID
hydromorphone hydrochloride
INJECTABLE;INJECTION019034-004Apr 30, 2009APRXYesYes6,589,960► SubscribeYY
Fresenius Kabi Usa
DILAUDID
hydromorphone hydrochloride
INJECTABLE;INJECTION019034-005Apr 30, 2009APRXYesYes6,589,960► SubscribeYY
Fresenius Kabi Usa
DILAUDID-HP
hydromorphone hydrochloride
INJECTABLE;INJECTION019034-001Jan 11, 1984APRXYesYes6,589,960► SubscribeY
Fresenius Kabi Usa
DILAUDID-HP
hydromorphone hydrochloride
INJECTABLE;INJECTION019034-002Aug 4, 1994DISCNNoNo6,589,960► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,589,960

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,512,117 Hydromorphone and hydrocodone compositions and methods for their synthesis► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,589,960

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria402937► Subscribe
Austria500257► Subscribe
Australia1595701► Subscribe
Canada2389193► Subscribe
Canada2674424► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Baxter
Moodys
McKesson
Chubb
Covington
AstraZeneca
Daiichi Sankyo
UBS
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot